Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Lessons to Be Learned: Farewell to Exubera

October 23, 2007

Analysis of:Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com

There remains a very important message to be learned from from Pfizer closing the doors on Exubera: physicians and other prescribers are not yet ready to embrace inhaled insulin. Despite the clinical results that Big Pharma may present, many health care professionals are incredibly reluctant to prescribe a new product that could end up being the next Vioxx or Avandia. Spirometry, long-term effects to the pulmonary system, and absorption rates are just a few of the red flags raised.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS